A Multiple-Center, Retrospective Study of Characteristics and Outcomes of Hospitalized COVID-19 Patients with Cardiovascular Disease in North Iran.
COVID-19
Iran
SARS-CoV-2
cardiac disease
cardiovascular disease
Journal
Ethiopian journal of health sciences
ISSN: 2413-7170
Titre abrégé: Ethiop J Health Sci
Pays: Ethiopia
ID NLM: 101224773
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
13
07
2022
accepted:
08
09
2022
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
11
3
2023
Statut:
ppublish
Résumé
In this retrospective study, we investigated the outcomes and demographic characteristics of COVID-19 patients with and without a history of CVD. This large retrospective, multicenter study was performed on inpatients with suspected COVID-19 pneumonia who were admitted across four hospitals in Babol, Northern Iran.Demographic data, clinical data, and cycle threshold value (Ct) results of Real Time PCR were obtained. Then, participants were divided into two groups: (1) cases with CVDs, (2) cases without CVDs. A total of 11097 suspected COVID-19 cases with a mean ± SD age of 53 ±25.3 (range: 0 to 99) years were involved in the present study. Out of whom 4599 (41.4%) had a positive RT-PCR result. Of those, 1558 (33.9%) had underlying CVD. Patients with CVD had significantly more co-morbidities such as hypertension, kidney disease, and diabetes. Moreover, 187 (12%) and 281 (9.2%) of patients with and without CVD died, respectively. Also, mortality rate was significantly high among the three groups of Ct value in patients with CVD, with the highest mortality in those with Ct between 10 and 20 (Group A = 19.9%). In summary, our results highlight that CVD is a major risk factor for hospitalization and the severe consequences of COVID-19. Death in CVD group is significantly higher compared to non-CVD. In addition, the results show that age-related diseases can be a serious risk factor for the severe consequences of COVID-19.
Sections du résumé
Background
UNASSIGNED
In this retrospective study, we investigated the outcomes and demographic characteristics of COVID-19 patients with and without a history of CVD.
Methods
UNASSIGNED
This large retrospective, multicenter study was performed on inpatients with suspected COVID-19 pneumonia who were admitted across four hospitals in Babol, Northern Iran.Demographic data, clinical data, and cycle threshold value (Ct) results of Real Time PCR were obtained. Then, participants were divided into two groups: (1) cases with CVDs, (2) cases without CVDs.
Results
UNASSIGNED
A total of 11097 suspected COVID-19 cases with a mean ± SD age of 53 ±25.3 (range: 0 to 99) years were involved in the present study. Out of whom 4599 (41.4%) had a positive RT-PCR result. Of those, 1558 (33.9%) had underlying CVD. Patients with CVD had significantly more co-morbidities such as hypertension, kidney disease, and diabetes. Moreover, 187 (12%) and 281 (9.2%) of patients with and without CVD died, respectively. Also, mortality rate was significantly high among the three groups of Ct value in patients with CVD, with the highest mortality in those with Ct between 10 and 20 (Group A = 19.9%).
Conclusions
UNASSIGNED
In summary, our results highlight that CVD is a major risk factor for hospitalization and the severe consequences of COVID-19. Death in CVD group is significantly higher compared to non-CVD. In addition, the results show that age-related diseases can be a serious risk factor for the severe consequences of COVID-19.
Identifiants
pubmed: 36890939
doi: 10.4314/ejhs.v33i1.2
pii: jEJHS.v33.i1.pg3
pmc: PMC9987289
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-12Informations de copyright
© 2023 Abazar, P. et al.
Références
Biol Sex Differ. 2017 Oct 24;8(1):33
pubmed: 29065927
Front Cardiovasc Med. 2021 Sep 09;8:732518
pubmed: 34568465
Front Public Health. 2021 Feb 16;9:559595
pubmed: 33665182
Viruses. 2021 Feb 11;13(2):
pubmed: 33670360
Mol Biol Rep. 2020 Jul;47(7):5365-5376
pubmed: 32601923
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750524
pubmed: 29355081
J Cardiovasc Thorac Res. 2021;13(4):355-363
pubmed: 35047140
J Cardiovasc Thorac Res. 2021;13(3):181-189
pubmed: 34630964
Glob Heart. 2020 Sep 22;15(1):64
pubmed: 33150129
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Int J Infect Dis. 2021 Oct;111:333-335
pubmed: 34403784
J Res Med Sci. 2021 Sep 30;26:82
pubmed: 34759999
Eur Respir J. 2021 Jul 20;58(1):
pubmed: 34172468
J Diabetes Metab Disord. 2021 Feb 26;20(1):905-917
pubmed: 33654683
Adv Exp Med Biol. 2021;1321:81-96
pubmed: 33656715
Ann Am Thorac Soc. 2021 May;18(5):900-903
pubmed: 33119425
Open Forum Infect Dis. 2021 Aug 31;8(9):ofab453
pubmed: 34584900
BMJ Open. 2021 Feb 22;11(2):e045482
pubmed: 33619201
Caspian J Intern Med. 2022;13(Suppl 3):244-253
pubmed: 35872672
Ethiop J Health Sci. 2021 Mar;31(2):429-438
pubmed: 34158795
Saudi Pharm J. 2021 Jul;29(7):682-691
pubmed: 34400862
PLoS One. 2020 Dec 7;15(12):e0243191
pubmed: 33284825
Expert Rev Anti Infect Ther. 2021 Jan;19(1):23-33
pubmed: 32703036
J Infect Dev Ctries. 2021 Oct 31;15(10):1408-1414
pubmed: 34780363
Int J Womens Health. 2014 Jan 24;6:131-9
pubmed: 24493934
J Neurovirol. 2021 Oct;27(5):691-701
pubmed: 34546547
Heart. 2021 Mar;107(5):373-380
pubmed: 33334865
J Cell Physiol. 2021 Jan;236(1):49-54
pubmed: 32542735
Glob Health Res Policy. 2020 Mar 2;5:6
pubmed: 32226823
Int J Infect Dis. 2020 Dec;101:160-166
pubmed: 32992013
Int J Clin Pract. 2022 Feb 28;2022:1455708
pubmed: 35685485
J Clin Virol. 2020 Jun;127:104378
pubmed: 32353762
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
An Acad Bras Cienc. 2017 Jan-Mar;89(1):285-299
pubmed: 28423084
Ethiop J Health Sci. 2021 Nov;31(6):1099-1108
pubmed: 35392339
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910